Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

14/11/2024 - 05:05

- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients -

Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer
Initial Data From At Least One Additional Arm of the Phase 2a Portion of the IMM-1-104 Phase 1/2a Trial Expected by Year End -
- Cash Runway into Fourth Quarter 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
3721 Views
Comment
Sign in to post a comment